Pyrotinib as a therapeutic for HER2-positive breast cancer.
作者信息
Kioutchoukova Ivelina, Lucke-Wold Brandon P
机构信息
College of Medicine, University of Florida, Gainesville, Florida, USA.
Department of Neurosurgery, University of Florida, Gainesville, Florida, USA.
出版信息
Transl Cancer Res. 2023 Jun 30;12(6):1376-1379. doi: 10.21037/tcr-23-333. Epub 2023 Jun 1.
Abstract
摘要
相似文献
1
Pyrotinib as a therapeutic for HER2-positive breast cancer.吡咯替尼作为HER2阳性乳腺癌的一种治疗药物。
Transl Cancer Res. 2023 Jun 30;12(6):1376-1379. doi: 10.21037/tcr-23-333. Epub 2023 Jun 1.
2
Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report.人表皮生长因子受体 2 阳性转移性乳腺癌伴新型表皮生长因子受体-ZNF880 融合和表皮生长因子受体 E114K 突变，吡咯替尼治疗有效：一例报告。
Medicine (Baltimore). 2020 Dec 18;99(51):e23406. doi: 10.1097/MD.0000000000023406.
3
Case Report: Significant Efficacy of Pyrotinib in the Treatment of Extensive Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Cutaneous Metastases: A Report of Five Cases.病例报告：吡咯替尼治疗广泛人表皮生长因子受体2阳性乳腺癌皮肤转移的显著疗效：5例报告
Front Oncol. 2021 Dec 16;11:729212. doi: 10.3389/fonc.2021.729212. eCollection 2021.
4
The efficacy and safety of using pyrotinib combined with capecitabine as neoadjuvant therapy in elderly patients with HER2-positive breast cancer: a single-arm prospective clinical trial.吡咯替尼联合卡培他滨作为老年HER2阳性乳腺癌患者新辅助治疗的疗效和安全性：一项单臂前瞻性临床试验。
Gland Surg. 2023 Feb 28;12(2):208-214. doi: 10.21037/gs-23-11. Epub 2023 Feb 27.
5
Durable clinical benefit from pyrotinib combined with carboplatin in HER2-positive relapsed breast cancer previously treated with taxanes, anthracyclines, and trastuzumab.吡咯替尼联合卡铂治疗既往紫杉类、蒽环类和曲妥珠单抗治疗的 HER2 阳性复发转移性乳腺癌患者的持久临床获益。
Ann Palliat Med. 2020 Sep;9(5):3684-3689. doi: 10.21037/apm-20-1363.
6
Pyrotinib-Containing Neoadjuvant Therapy in Patients With HER2-Positive Breast Cancer: A Multicenter Retrospective Analysis.HER2阳性乳腺癌患者含吡咯替尼的新辅助治疗：一项多中心回顾性分析
Front Oncol. 2022 Apr 7;12:855512. doi: 10.3389/fonc.2022.855512. eCollection 2022.
7
Pyrotinib-based treatments in HER2-positive breast cancer patients with brain metastases.吡咯替尼治疗 HER2 阳性乳腺癌伴脑转移患者。
Ann Med. 2022 Dec;54(1):3085-3095. doi: 10.1080/07853890.2022.2139411.
8
Significant response to the combination of pyrotinib and letrozole in a patient with metastatic HER2-positive and hormone receptor-positive breast cancer: a case report.曲妥珠单抗联合来曲唑治疗 HER2 阳性、激素受体阳性转移性乳腺癌患者的疗效显著：病例报告。
Ann Palliat Med. 2021 Sep;10(9):10124-10129. doi: 10.21037/apm-21-2522.
9
Cardiotoxicity monitoring of pyrotinib in combination with nab-paclitaxel, doxorubicin, and cyclophosphamide in HER2-positive breast cancer: a single-armed clinical trial.吡咯替尼联合白蛋白结合型紫杉醇、多柔比星和环磷酰胺治疗HER2阳性乳腺癌的心脏毒性监测：一项单臂临床试验
Gland Surg. 2022 Apr;11(4):742-750. doi: 10.21037/gs-22-161.
10
Pyrotinib combining with radiotherapy on breast cancer with brain metastasis.吡咯替尼联合放疗治疗乳腺癌脑转移。
Exp Biol Med (Maywood). 2023 Jan;248(2):106-116. doi: 10.1177/15353702221142605. Epub 2022 Dec 19.
引用本文的文献
1
Efficacy of Pyrotinib combined with Trastuzumab in the treatment of patients with human epidermal growth factor receptor-2 positive breast cancer.吡咯替尼联合曲妥珠单抗治疗人表皮生长因子受体2阳性乳腺癌患者的疗效
Pak J Med Sci. 2025 Jun;41(6):1749-1754. doi: 10.12669/pjms.41.6.11682.
2
A diagnostic test of two-dimensional ultrasonic feature extraction based on artificial intelligence combined with blood flow Adler classification and contrast-enhanced ultrasound for predicting -positive breast cancer.一种基于人工智能结合血流阿德勒分类及超声造影的二维超声特征提取诊断试验，用于预测阳性乳腺癌。
Transl Cancer Res. 2025 Jan 31;14(1):640-650. doi: 10.21037/tcr-24-2182. Epub 2025 Jan 21.
3
Short-term efficacy and safety of neoadjuvant pyrotinib plus taxanes for early HER2-positive breast cancer: a single-arm exploratory phase II trial.吡咯替尼联合紫杉类药物新辅助治疗早期HER2阳性乳腺癌的短期疗效和安全性：一项单臂探索性II期试验
Gland Surg. 2024 Mar 27;13(3):374-382. doi: 10.21037/gs-24-38. Epub 2024 Mar 22.
4
Efficacy and Safety of Radiotherapy Combined with Pyrotinib in the Treatment of HER2-Positive Breast Cancer with Brain Metastases.放疗联合吡咯替尼治疗HER2阳性脑转移乳腺癌的疗效与安全性
Breast Cancer (Dove Med Press). 2023 Nov 17;15:841-853. doi: 10.2147/BCTT.S440427. eCollection 2023.
5
Clinical and pathological factors and outcome of central nervous system metastasis in breast cancer.乳腺癌中枢神经系统转移的临床病理因素及预后
Front Oncol. 2023 Sep 19;13:1247402. doi: 10.3389/fonc.2023.1247402. eCollection 2023.
本文引用的文献
1
Pyrotinib for HER2-positive metastatic breast cancer: a systematic review and meta-analysis.吡咯替尼用于HER2阳性转移性乳腺癌：一项系统评价和荟萃分析。
Transl Cancer Res. 2023 Feb 28;12(2):247-256. doi: 10.21037/tcr-22-1746. Epub 2023 Feb 21.
2
Protocol for pyrotinib cardiac safety in patients with HER2-positive early or locally advanced breast cancer-The EARLY-MYO-BC study.吡咯替尼治疗HER2阳性早期或局部晚期乳腺癌患者心脏安全性的研究方案——EARLY-MYO-BC研究
Front Cardiovasc Med. 2023 Feb 10;10:1021937. doi: 10.3389/fcvm.2023.1021937. eCollection 2023.
3
Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial.吡咯替尼、曲妥珠单抗和多西他赛新辅助治疗 HER2 阳性乳腺癌（PHEDRA）：一项双盲、随机 3 期试验。
BMC Med. 2022 Dec 27;20(1):498. doi: 10.1186/s12916-022-02708-3.
4
Cost-Effectiveness of Pyrotinib Plus Capecitabine versus Lapatinib Plus Capecitabine for the Treatment of HER2-Positive Metastatic Breast Cancer in China: A Scenario Analysis of Health Insurance Coverage.吡咯替尼联合卡培他滨对比拉帕替尼联合卡培他滨治疗中国 HER2 阳性转移性乳腺癌的成本-效果分析：基于医保覆盖情景的探讨
Curr Oncol. 2022 Aug 23;29(9):6053-6067. doi: 10.3390/curroncol29090476.
5
Efficacy of tyrosine kinase inhibitors for the treatment of patients with HER2-positive breast cancer with brain metastases: a systematic review and meta-analysis.酪氨酸激酶抑制剂治疗 HER2 阳性乳腺癌伴脑转移患者的疗效：系统评价和荟萃分析。
ESMO Open. 2022 Jun;7(3):100501. doi: 10.1016/j.esmoop.2022.100501. Epub 2022 May 30.
6
Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial.吡咯替尼联合卡培他滨治疗人表皮生长因子受体 2 阳性乳腺癌伴脑转移患者（PERMEATE）：一项多中心、单臂、两队列、Ⅱ期临床试验。
Lancet Oncol. 2022 Mar;23(3):353-361. doi: 10.1016/S1470-2045(21)00716-6. Epub 2022 Jan 31.
7
How we treat patients with metastatic HER2-positive breast cancer.我们如何治疗转移性 HER2 阳性乳腺癌患者。
ESMO Open. 2022 Feb;7(1):100343. doi: 10.1016/j.esmoop.2021.100343. Epub 2022 Jan 4.
8
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement.定义癌症治疗的心血管毒性：国际心脏肿瘤学会（IC-OS）共识声明。
Eur Heart J. 2022 Jan 31;43(4):280-299. doi: 10.1093/eurheartj/ehab674.
9
Multiple Administrations of Itraconazole Increase Plasma Exposure to Pyrotinib in Chinese Healthy Adults.伊曲康唑多次给药增加中国健康成年人吡咯替尼的血浆暴露。
Drug Des Devel Ther. 2021 Jun 10;15:2485-2493. doi: 10.2147/DDDT.S312310. eCollection 2021.
10
Current and Future Management of HER2-Positive Metastatic Breast Cancer.人表皮生长因子受体 2 阳性转移性乳腺癌的当前和未来管理。
JCO Oncol Pract. 2021 Oct;17(10):594-604. doi: 10.1200/OP.21.00172. Epub 2021 Jun 2.
Zotero 插件